Pancreatic Cancer Research

ResearcherJapanese Foundation For Cancer ResearchActive in the last 2 years

Takatsugu Ishimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1852-1835; OpenAlex author ID A5018669075. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasi… Co-author DOI 10.1007/s00535-024-02195-8↗
  2. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. Last author DOI 10.1172/jci.insight.163022↗
  3. Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer. Last author DOI 10.1111/cas.15495↗
  4. Editorial: Targeting Pancreatic Cancer: Strategies and Hopes. Last author DOI 10.3389/fonc.2022.873682↗
  5. Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer. Last author DOI 10.1016/j.canlet.2021.09.007↗
  6. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15071↗
  7. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  8. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  9. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Last author DOI 10.1111/cas.13467↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 4 shared papers, 2021–2025 · strength 0.56
  2. Katsunori Imai · 6 shared papers, 2018–2023 · strength 0.56
  3. Fumimasa Kitamura · 4 shared papers, 2021–2023 · strength 0.46
  4. Kota Arima · 5 shared papers, 2018–2022 · strength 0.42
  5. Luke Bu · 4 shared papers, 2018–2023 · strength 0.40
  6. Rumi Itoyama · 4 shared papers, 2018–2023 · strength 0.40
  7. Tomoyuki Uchihara · 4 shared papers, 2018–2022 · strength 0.40
  8. Hideo Baba · 4 shared papers, 2018–2023 · strength 0.39
  9. Tatsunori Miyata · 4 shared papers, 2018–2021 · strength 0.37
  10. Kanjoormana Aryan Manu · 1 shared paper, 2022 · strength 0.26
  11. Kuzhuvelil B. Harikumar · 1 shared paper, 2022 · strength 0.26
  12. Norio Uemura · 2 shared papers, 2021–2023 · strength 0.26
  13. Yuki Kitano · 3 shared papers, 2018–2021 · strength 0.24
  14. Naotaka Kugiyama · 1 shared paper, 2025 · strength 0.21
  15. Yasuhito Tanaka · 1 shared paper, 2025 · strength 0.21
  16. Katsuya Nagaoka · 1 shared paper, 2025 · strength 0.21
  17. Hajime Yamazaki · 1 shared paper, 2025 · strength 0.21
  18. Masayo Tsukamoto · 3 shared papers, 2018–2019 · strength 0.21
  19. Akira Chikamoto · 3 shared papers, 2018–2019 · strength 0.21
  20. Shigeki Nakagawa · 3 shared papers, 2018–2019 · strength 0.21
  21. Hirohisa Okabe · 3 shared papers, 2018–2019 · strength 0.21
  22. Naoki Umezaki · 2 shared papers, 2018–2019 · strength 0.14
  23. Takanobu Yamao · 2 shared papers, 2018–2019 · strength 0.14
  24. Daisuke Hashimoto · 2 shared papers, 2018 · strength 0.13
  25. Kosuke Mima · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.